SG11202102379XA - O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors - Google Patents
O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsInfo
- Publication number
- SG11202102379XA SG11202102379XA SG11202102379XA SG11202102379XA SG11202102379XA SG 11202102379X A SG11202102379X A SG 11202102379XA SG 11202102379X A SG11202102379X A SG 11202102379XA SG 11202102379X A SG11202102379X A SG 11202102379XA SG 11202102379X A SG11202102379X A SG 11202102379XA
- Authority
- SG
- Singapore
- Prior art keywords
- glucopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862733484P | 2018-09-19 | 2018-09-19 | |
US201862750000P | 2018-10-24 | 2018-10-24 | |
PCT/US2019/051661 WO2020061150A1 (en) | 2018-09-19 | 2019-09-18 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102379XA true SG11202102379XA (en) | 2021-04-29 |
Family
ID=68073263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102379XA SG11202102379XA (en) | 2018-09-19 | 2019-09-18 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220041586A1 (en) |
EP (1) | EP3853226A1 (en) |
JP (1) | JP2022500472A (en) |
KR (1) | KR20210060513A (en) |
CN (1) | CN113166137A (en) |
AU (1) | AU2019344922A1 (en) |
BR (1) | BR112021004739A2 (en) |
CA (1) | CA3113009A1 (en) |
CL (1) | CL2021000646A1 (en) |
CO (1) | CO2021004873A2 (en) |
CR (1) | CR20210181A (en) |
IL (1) | IL281514A (en) |
JO (1) | JOP20210036A1 (en) |
MA (1) | MA53648A (en) |
MX (1) | MX2021003232A (en) |
PE (1) | PE20211591A1 (en) |
PH (1) | PH12021550439A1 (en) |
SG (1) | SG11202102379XA (en) |
TW (1) | TW202031651A (en) |
UY (1) | UY38376A (en) |
WO (1) | WO2020061150A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL300365A (en) * | 2020-08-03 | 2023-04-01 | Biogen Ma Inc | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
KR102533471B1 (en) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | COMPOUNDS hAVING O-GLCNACASE INHIBITORY ACTIVITY AND USE THEREOF |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013075083A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2014124418A1 (en) | 2013-02-11 | 2014-08-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
DK2970272T3 (en) * | 2013-03-14 | 2019-04-23 | Merck Patent Gmbh | glycosidase |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
CA3045957A1 (en) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Monocyclic oga inhibitor compounds |
CA3044762A1 (en) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
AR110747A1 (en) | 2017-01-27 | 2019-05-02 | Lilly Co Eli | 5-METHYL-1,2,4-OXADIAZOL-3-ILO COMPOUNDS |
EP3765458B1 (en) * | 2018-03-14 | 2023-01-11 | Biogen MA Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors |
-
2019
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/en active Application Filing
- 2019-09-18 TW TW108133538A patent/TW202031651A/en unknown
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/en active Pending
- 2019-09-18 AU AU2019344922A patent/AU2019344922A1/en active Pending
- 2019-09-18 US US17/276,502 patent/US20220041586A1/en active Pending
- 2019-09-18 CA CA3113009A patent/CA3113009A1/en active Pending
- 2019-09-18 UY UY0001038376A patent/UY38376A/en unknown
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/en unknown
- 2019-09-18 MA MA053648A patent/MA53648A/en unknown
- 2019-09-18 JP JP2021515045A patent/JP2022500472A/en active Pending
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/en unknown
- 2019-09-18 CN CN201980060829.1A patent/CN113166137A/en active Pending
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/en unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/en unknown
- 2019-09-18 CR CR20210181A patent/CR20210181A/en unknown
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/en unknown
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-15 IL IL281514A patent/IL281514A/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/en unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210060513A (en) | 2021-05-26 |
CN113166137A (en) | 2021-07-23 |
EP3853226A1 (en) | 2021-07-28 |
TW202031651A (en) | 2020-09-01 |
MA53648A (en) | 2021-07-28 |
IL281514A (en) | 2021-04-29 |
CL2021000646A1 (en) | 2021-09-03 |
US20220041586A1 (en) | 2022-02-10 |
JOP20210036A1 (en) | 2021-02-25 |
CO2021004873A2 (en) | 2021-07-30 |
PH12021550439A1 (en) | 2021-11-29 |
MX2021003232A (en) | 2021-07-16 |
BR112021004739A2 (en) | 2021-06-01 |
JP2022500472A (en) | 2022-01-04 |
CA3113009A1 (en) | 2020-03-26 |
AU2019344922A1 (en) | 2021-03-25 |
UY38376A (en) | 2020-04-30 |
PE20211591A1 (en) | 2021-08-18 |
CR20210181A (en) | 2021-07-01 |
WO2020061150A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283639A (en) | Kif18a inhibitors | |
IL291430A (en) | Mcl-1 inhibitors | |
IL277006A (en) | Cd73 inhibitors | |
IL269196A (en) | Novel inhibitors | |
IL304348A (en) | Cd73 inhibitors | |
GB201705971D0 (en) | Inhibitor compounds | |
ZA201907136B (en) | Ip6k inhibitors | |
IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
IL276013A (en) | Pi4kiiibeta inhibitors | |
GB201819126D0 (en) | Inhibitor compounds | |
GB201612860D0 (en) | Inhibitors | |
EP3600301A4 (en) | Kdm4 inhibitors | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
IL279419A (en) | Ccl5 inhibitors | |
GB201807845D0 (en) | Kinase Inhibitors | |
GB201812462D0 (en) | Inhibitors | |
GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
GB201905476D0 (en) | MAPA4K4 Inhibitors | |
GB201809939D0 (en) | Eastase inhibitor | |
GB201721465D0 (en) | Inhibitors | |
GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
GB201819136D0 (en) | Inhibitor compounds | |
GB201806131D0 (en) | Inhibitor compounds |